Titre complet :
Can personalized medicine be used to reduce treatment-related neurotoxicity among children with acut
Conférencier :
Peter Cole, MD (pour l'axe Maladies immunitaires et cancers)
Professeur agrégé de pédiatrie, Collège de médecine Albert Einstein et Hôpital pour enfants de Montefiore.
Résumé :
Drawing on a background in pediatric oncology and the molecular pharmacology of chemotherapy, my research focuses on reducing intellectual disabilities induced by anticancer therapy. My laboratory analyzes biomarkers in blood and cerebrospinal fluid, collected from children treated for acute lymphoblastic leukemia, to identify correlates and models predictive of treatment-related toxicities. Using an animal model of chemotherapy-induced cognitive dysfunction, we are defining the underlying pathophysiology and identifying protective interventions. In addition, as vice Chair of the Children's Oncology Group Hodgkin Lymphoma Committee, I have been actively involved in developing innovative therapeutic protocols for children and young adults with Hodgkin lymphoma.
